Uses
Cysto-Conray II is indicated for use in retrograde cystography and cystourethrography.
Source: US FDA prescribing information
Molecule
Iothalamate is a radiographic contrast agent indicated in retrograde cystography and cystourethrography. It is available as injection for ureteral use. MedsAcross supplies Iothalamate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Cysto-Conray II is indicated for use in retrograde cystography and cystourethrography.
Source: US FDA prescribing information
Patient Preparation Unless contraindicated, an appropriate laxative is given the night before the examination. Radiographic Technique The radiographic procedure normally employed for cystography and cystourethrography should be employed. A preliminary radiograph is recommended before the contrast agent is administered. Administration Sterile catherization is essential. Cysto-Conray II may be introduced by gravity flow using an appropriate venoclysis set or by syringe. Excessive pressure should be avoided with any method of administration. Usual Dosage Cystography and Cystourethrography – Either Conray 43 supplied at 43% w/v or Cysto-Conray II supplied at a 17.2% w/v concentration may be used for these procedures. The desired concentration will vary depending upon the patient’s size and age and also with the technique and equipment used.
Source: US FDA prescribing information
See WARNINGS concerning inadvertant intrathecal administration.
Source: US FDA prescribing information
NOT FOR INTRAVASCULAR ADMINISTRATION NOT FOR INTRATHECAL USE SEVERE ADVERSE EVENTS – INADVERTENT INTRATHECAL ADMINISTRATION: Serious adverse reactions have been reported due to the inadvertent intrathecal administration of iodinated contrast media that are not indicated for intrathecal use. These serious adverse reactions include: death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. Special attention must be given to ensure that this drug product is not administered intrathecally.
Source: US FDA prescribing information
Irritation of the bladder or ureter, common to some degree to all contrast media administered for retrograde urographic procedures, may occasionally occur. As with all contrast media, intravasation may lead to hypersensitivity reactions such as a sense of warmth, flushing, sneezing, sweating, chills, fever, urticaria, laryngeal edema, bronchospasm, hypertension, hypotension, cardiac arrhythmias and cardiac arrest. Adverse reactions associated with procedural technique include injury to the urethra, bladder, ureter, and introduction of infection. In the event of serious or anaphylactoid reactions, it should be kept in mind that the reactions known to occur with intravenous administration of radiopaque contrast materials are possible.
Source: US FDA prescribing information
Store at 20° to 25°C (68° to 77°F). If this occurs, the containers should be brought to room temperature. This product is sensitive to light and must be protected from strong daylight or direct exposure to the sun.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Iothalamate, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Cysto-Conray II 43000 mg/250 mL injectionUreteral | Liebel-Flarsheim | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 16 August 1962 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Iothalamate and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Iothalamate, including Cysto-Conray II.
Yes. The US FDA first approved Iothalamate on 16 August 1962, according to Drugs@FDA.
No listed presentation of Iothalamate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Iothalamate is classified under ATC code V08AA04 (Iothalamate).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.